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Abstract
Background: The ability to disrupt the function of a specific protein on a rapid time scale provides a powerful tool for
biomedical research. Specific proteases provide a potential method to selectively cleave a chosen protein, but rapid control
of protease activity is difficult.
Methodology/Principal Findings: A heterologous expression system for rapid target-directed proteolysis in mammalian
cells was developed. The system consists of an inducible NIa protease from the tobacco etch virus (TEVp) and a chosen
protein into which a TEVp substrate recognition sequence (TRS) has been inserted. Inducible activity was conferred to the
TEVp using rapamycin-controlled TEVp fragment complementation. TEVp activity was assayed using a FRET-based reporter
construct. TEVp expression was well tolerated by mammalian cells and complete cleavage of the substrate was possible.
Cleavage at 37uC proceeded exponentially with a time constant of approximately 150 minutes. Attempts to improve
cleavage efficiency were hampered by substantial background activity, which was attributed to inherent affinity between
the TEVp fragments. A second TEVp assay, based on changes in inactivation of a modified KV3.4 channel, showed that
functional properties of a channel can be using altered using an inducible TEVp system. Similar levels of background activity
and variability were observed in both electrophysiological and FRET assays.
Conclusions/Significance: The results suggested that an optimum level of TEVp expression leading to sufficient inducible
activity (with minimal background activity) exists but the variability in expression levels between cells makes the present
system rather impractical for single cell experiments. The system is likely to be more suitable for experiments in which the
cell-to-cell variability is less of an issue; for example, in experiments involving large populations of cells.
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Introduction
The ability to ablate the function of a specific protein is a
powerful tool for investigating protein function. Two approaches
are commonly employed to achieve this goal. First, pharmacolog-
ical agents, such as receptor antagonists, are used to acutely inhibit
protein function. This approach is both rapid and, in some cases,
selective. However, appropriately selective small molecule agents
are often unavailable, especially for intracellular targets, and
pharmacological effects are difficult to spatially constrain at the
cellular level. Second, genetic approaches are used to reduce or
eliminate protein expression by targeting the gene coding for the
protein of interest (genetic knock-out) or interfering with gene
transcription or translation (RNA interference, antisense RNA).
These methods target protein synthesis and thus turnover of
endogenous protein must occur before a phenotype is realized.
During this delay, compensatory mechanisms can occur which
confound data interpretation [1–4]. Genetic mechanisms, howev-
er, are broadly applicable if sequence information is available.
Moreover, targeted expression strategies can be used to restrict
modification to a small subset of cells in living animals. Thus, a
method to modify the function of a specific protein on a rapid
timescale (e.g.,1 hr) using both gene expression and pharmaco-
logical approaches would benefit from the advantages of both
technologies.
A potential approach is to use a protease whose activity can be
temporally controlled by small molecules and can specifically
cleave the protein of interest at an identified site thereby altering
or eliminating function. The tobacco etch virus NIa protease
(TEVp) is a good candidate for this strategy as the canonical
substrate recognition sequence (ENLYFQ/G) is sufficiently unique
to ensure targeting specificity [5]. Moreover, TEVp has high
catalytic activity [6], works over a broad pH range, and retains
activity at temperatures from 4–37uC. These characteristics have
led to the increasing in vitro use of TEVp in recombinant protein
preparation, primarily for removing fusion tags from newly
synthesized protein [7]. Consequently, high resolution structural
information is available [8,9] and efforts have been made to
improve enzyme activity [6,10] and solubility [11,12].
Temporal control of TEVp enzyme activity, which is normally
constitutive, can be conferred by using protein-fragment comple-
mentation (PFC), a technique originally developed to investigate
protein-protein interactions [13]. In this system, a reporter protein
is split into nonfunctional fragments and fused to potentially
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partners brings the reporter protein fragments into close proximity
resulting in assembly of a functional protein. Recently, TEVp has
been used in a protein-fragment complementation assay to
investigate protein-protein interactions [14]. In these studies, we
used a rapamycin-mediated heterodimerization system combined
with PFC to confer temporal control to TEVp activity. Split TEVp
fragments were fused to either FK506 binding protein (FKBP12)
or the FKBP12-rapamycin-binding domain of FRAP (FRB). Upon
application of rapamycin, a cell permeable molecule, FKBP12 and
FRB rapidly associate, resulting in reconstitution of TEVp enzyme
activity. To quantify TEVp activity in living cells, we measured
Fo ¨rster resonance energy transfer (FRET) of reporter proteins
comprised of fluorescent proteins linked together with a peptide
containing a TEVp substrate recognition sequence (TRS). We also
employed electrophysiological assays to explore the potential for
acute post-translational modification of ion channels during patch
clamp experiments. The results provide insights into both the
potential and challenges of constructing genetically expressible
systems for the rapid modification of targeted proteins in living
cells.
Results
Quantification of TEVp enzyme activity in living cells
using Fo ¨rster resonance energy transfer measurements
A FRET-based assay based on wide-field fluorescence microscopy
w a su s e dt oq u a n t i f yT E V pa c t i v ity. The genetically encoded
substrate consisted of adonor,Cerulean [15], and an acceptor, Venus
[16], fluorescent protein (FP) joined by a linker containing a TEVp
recognition sequence (TRS; Fig. 1A). FRET was measured from
sensitized acceptor emission using a modification of the 3-cube
approach [17–19] and converted to FRET efficiency, as described
previously [20]. This method also allows calculation of donor to
acceptor ratio ([D]/[A]). For simple systems such as this, the
measuredorapparentFRETefficiencyisaproductoftheintrinsic(or
maximum) FRET efficiency and fractional occupancy of donor with
acceptor. Thus, FRET efficiency represents a linear measurement of
substrate cleavage that is instrument-independent (Fig. 1Aii and B).
As viral TEVp is expressed in plants, a codon-optimized (human)
sequence was synthesized (GenBank accession # DQ516974) by a
commercial source to optimize translation efficiency in mammalian
cells. This sequence also contained a point mutation (S219V)
Figure 1. FRET-based assay of TEVp activity. A)( i) A schematic representation of the FRET sensor plasmid. (ii) Diagram showing the basis of the
TEVp activity assay. B) Typical unprocessed donor, FRET and acceptor images and pseudocolored FRET efficiency images calculated from the
intensities of the unprocessed images. Cells displaying high (C34V alone) and low (C34V + TEVp) FRET efficiencies are shown. C) Amino acid sequence
of linkers between fluorescent proteins of the FRET sensor. The TEVp recognition sequence is shown in red and the cleavage site is marked with a
dashed line. Differences between the linkers are shown in bold type. D) Scatter plot showing FRET efficiencies of individual cells transfected with
100 ng of one of the FRET sensor plasmid alone and with an increasing amount of TEVp plasmid vector. The median FRET efficiency is marked with a
red bar. # represents a significant difference (P,0.05) between the median FRET efficiency of control cells transfected with sensor alone (open
circles) and cells co-transfected with the amount of TEVp plasmid indicated (solid circles).
doi:10.1371/journal.pone.0007474.g001
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removed a potentially inhibitory sequence [9]. Subsequently, three
additional mutations (T17S, N68D, I77V) were introduced into the
TEVp sequence to improve solubility [12]. To assess TEVp activity
in living cells,variousquantitiesofTEVp vectoralongwitha reporter
construct, C32V, were transfected into HeLa cells. C32V codes for a
protein consisting of Cerulean and Venus linked via a 32-residue
peptide that includes a canonical TEVp recognition sequence at the
C-terminus (Fig. 1C). Following overnight incubation at 36uC,FRET
efficiency for individual cells was determined (mean FRET efficiency
determined on a pixel-by-pixel basis over the entire cell) and
displayed as a scatter plot (Fig. 1D). We chose to graph the value for
each cell as this format conveys the most information for data sets
with moderate n values [21]. Moreover, for single cell assays (e.g.,
imaging and patch-clamp electrophysiology), the scatter in the data
heavily influences experimental design. In the absence of TEVp
expression, the FRET efficiency values were tightly clustered around
am e d i a no f3 5 %( n=71). For clarity, median FRET efficiencies
measured in the presence of TEVp constructs were normalized to
median FRET efficiencies measured from control cells transfected
with the reporter construct alone. Raw FRET efficiencies are plotted
in the Figures. Increasing quantities of TEVp cDNA produced
progressively larger decreases in median FRET efficiency (Fig. 1D).
In cells transfected with the highest mass of TEVp construct (850 ng),
there was a large variation in FRET efficiencies and only a moderate
reduction in median FRET efficiency (to 62% of the median FRET
efficiency measured from control cells transfected with C32V alone;
n=33), which indicates incomplete substrate cleavage. In addition,
the [D]/[A] increased from a median of 1.0 (interquartile range,
IQR, 1.0–1.1; n=34) to 2.0 (IQR 1.5–3.1; P,0.05; n=33). This
change suggested that the Venus species was degraded following
cleavage. Preliminary experiments suggest the proteasomal degrada-
tion was involved as the [D]/[A] could be maintained near 1 if the
cells were preincubated with MG-132, a cell permeant proteosome
inhibitor (unpublished data).
In order to prevent possibleinaccuracies in FRET calculations that
result from large changes in [D]/[A], a methionine was inserted into
the TRS at the P19 position (C32[M]V; Fig. 1C). At this position, the
resulting C-terminal cleavage product (i.e., Venus) should start with
methionine, as with most naturally occurring proteins. Previous
studies of TEVp substrate specificity, mostly performed in vitro,h a v e
indicated that the P19 position is tolerant to all substitutions except
proline [22]. Somewhat surprisingly, in cells transfected with 100 ng
C32[M]V and 850 ng TEVp, there was only a small decrease in the
median FRET efficiency (to 94% of the FRET efficiency measured
from control cells transfected with C32[M]V alone; n=35; Fig. 1D).
This finding indicates that methionine at the P19 position of the TRS
strongly inhibited cleavage and that amino acid substitutions at this
position may be more context sensitive than previously realized.
Consequently, a third construct, termed C34V, which contained a
FLAGH epitope (DYKDDDDKDG) located just downstream to the
TRS was tested (C34V; Fig. 1C). There was a dramatic reduction in
FRET efficiency in cells cotransfected with 100 ng TEVp (to 3% of
the median FRET efficiency from cells transfected with C34V alone,
n=71, ncontrol=64; Fig. 1D). Moreover, there was little spread in these
data, which indicates nearly complete substrate cleavage and the
[D]/[A] ratio following cleavage remained near 1 (0.93, n=71).
Thus, C34V appeared to be a sensitive detector for TEVp activity
and was used in all subsequent FRET-based experiments.
Generation of regulable TEVp via protein fragment
complementation
To make a TEVp with inducible enzyme activity, two strategies
were used: a PFC approach and by steric hindrance of the active
site. For the PFC method, the TEVp open reading frame was split
and the resulting N- and C-terminal fragments were fused to
FKBP12 and FKBP12-binding protein (FRP), respectively
(Fig. 2A). The choice of split sites was based on information
derived from the crystal structure of TEVp (Fig. 2B) or the existing
literature [14]. Split sites were chosen in domains with no clear
secondary structure or regions in which a high degree of flexibility
was inferred from the B-factor (atomic displacement parameter).
To test each of the split sites, HeLa cells were cotransfected with
450 ng of both split TEVp (sTEVp) fragment plasmids and 100 ng
C34V. Following overnight incubation to allow for protein
expression, FRET efficiency measurements were made from cells
exposed to 100 nM rapamycin for 3 hours at 37uC and untreated
control cells. Rapamycin incubation had no effect on C34V FRET
efficiency in the absence of TEVp fragment transfection (Fig. 2C).
Of the five split sites tested, three produced a significant reduction
in C34V FRET efficiency after rapamycin addition (90/91, 118/
119, and 136/137; Fig. 2C). Cells transfected with 118/119
sTEVp (site from Wehr et al. [14]) produced the largest reduction
in median FRET efficiency after rapamycin addition (to 3% of the
median FRET efficiency measured from control cells transfected
with C34V alone, n=68, ncontrol=81), but there was also a
significant reduction in FRET efficiency in the absence of
rapamycin (to 83% of the FRET efficiency measured from control
cells, n=64). This reduction suggested that appreciable back-
ground TEVp activity (‘‘leak’’) was present when large quantities
of 118/119 sTEVp were expressed.
The mass of 118/119 sTEVp construct used for transfection
was adjusted to provide optimal sTEVp activity (i.e. minimum
background TEVp activity and a high level of C34V cleavage after
rapamycin addition). As shown in Fig. 2D, at low sTEVp
expression levels (40 ng plasmid), there was little background
activity but many cells displayed inefficient cleavage of C34V. As
the amount of sTEVp used for transfection increased, an increase
in both cleavage of C34V in control cells and cells exposed to
rapamycin for 3 hours occurred. The optimum mass of sTEVp
used for transfection was 125 ng. In the absence of rapamycin, in
cells transfected with 125 ng sTEVp, there was a small decrease in
median FRET efficiency (to 96% of the FRET efficiency measured
from control cells transfected with C34V alone; n=77, ncontrol=74).
Following exposure to rapamycin for 3 hours, the median FRET
efficiency decreased to 3% of that of control cells (n=68). A similar
level of background activity occurred in cells transfected with 118/
119 sTEVp constructs lacking FRB and FKBP12 domains (Fig.
S1A). These results suggest that the background activity was
caused by spontaneous association of the TEVp fragments rather
than association of the FRB and FKBP12 domains in the absence
of rapamycin.
Cellular kinetics of TEVp action
To investigate the time course of sTEVp activity, cells were
transfected with 300 ng of each of the 118/119 sTEVp constructs
and 100 ng C34V. FRET efficiencies from different cells were
measured before rapamycin addition and at regular intervals for
4 hours in the presence of rapamycin at 37uC. A single
exponential curve was fitted to the median FRET efficiency at
each time point (n=15–30) using nonlinear regression. The time
constant (t) of the fitted line was 150 minutes (Fig. 2E). TEVp
produced in bacteria have a folding defect that reduces activity
when grown at 37uC (D.S. Waugh, personal communication) and
thus a similar experiment was run at 33uC. However, the
temperature reduction had little effect on the rate of proteolysis
(the t was 170 minutes, n=23–39; Fig. S1B) indicating that
differences between the constructs (e.g., introduced solubility
An Inducible TEV Protease
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7474Figure 2. Development of an inducible TEVp using protein fragment complementation. A)( i) Plasmids encoding TEVp fragments (sTEVp-
NT and sTEVp-CT) fused to rapamycin binding proteins (FRB and FKBP12). (ii) A representation of the rapamycin-induced complementation of sTEVp
and reconstitution of protease activity. B) Crystal structure of TEVp (from [8]) represented as a cartoon showing ‘B-factor’. An increased diameter of
the tube indicates a higher B-factor. The TRS of the substrate is shown in yellow and tested split sites are indicated in blue. The location of the
residues required to catalyze proteolysis are shown in white. The two fragments that result from a 118/119 split are shown in green and red. C)
Scatter plot showing FRET efficiencies of individual cells transfected with sTEVp constructs (split at the residues indicated). Cells were transfected with
150 ng of C34V alone, or cotransfected with 450 ng of each sTEVp plasmid. FRET efficiencies were measured from untreated cells and cells exposed
to rapamycin for 3 hours. D) Scatter plot showing FRET efficiencies of individual cells transfected with different amounts of 118/119 sTEVp constructs.
Measurements were taken from cells transfected with 100 ng of C34V alone, or cotransfected with the indicated amount of each sTEVp plasmid. FRET
efficiencies were measured from untreated control cells and cells exposed to rapamycin for 3 hours. # represents a significant difference between
control cells transfected with C34V alone and cells cotransfected with C34V and the sTEVp plasmids indicated. * represents a significant difference
between cells transfected with the indicated sTEVp constructs in the absence of rapamycin (open circles) and cells exposed to 100 nM rapamycin for
3 hours (solid circles). E) A plot showing the median FRET efficiencies of different cells transfected with 300 ng of 118/119 sTEVp constructs at various
time points after rapamycin addition. The time constant (t) was calculated from a single-exponential curve fitted to the data (n=15–30 cells at each
time point).
doi:10.1371/journal.pone.0007474.g002
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relationship between the occurrence of the folding defect and
temperature.
A simple model was employed to provide a framework for
further optimization:
ENzEC E ð1Þ
EzS ES EzP ð2Þ
where EN and EC are the N- and C-terminus fragments of TEVp,
E is the reconstituted or functional enzyme (TEVp), S is the
substrate (C34V), ES the enzyme-substrate complex, and P the
products of hydrolysis. The rate constants (k) are as indicated. It
was assumed that the formation of the functional enzyme occurs
rapidly once the EN-EC complex was formed (Equation 1) and that
the usual assumptions [23] underlying the Michaelis-Menten
formalism were made. From the time course data shown in Fig. 2E,
we can infer that mechanisms underlying TEVp reconstitution
(e.g., diffusion of rapamycin into the cell, formation of EN-EC
complex, and folding to form the functional enzyme) were
relatively rapid on this time scale (hundreds of minutes) as the
substrate concentration decreased monotonically with little
evidence of delay. As the time course was well approximated by
a single exponential function, we also infer that [S]%KM of the
reconstituted TEVp.
In parallel with the PFC strategy, we undertook a second
approach to construct an inducible TEVp system. For this
method, the idea was to occlude access to the TEVp active site
using a point mutant of the FKBP12 protein termed Fm [24].
When expressed, Fm forms homodimers that can subsequently be
disrupted by the addition of rapamycin. By fusing Fm proteins
fused to the N- and C-termini of TEVp, it was hypothesized that
TEVp activity would be ablated by steric hindrance of the catalytic
site. Addition of rapamycin would then restore enzyme activity by
disrupting the Fm-Fm interaction and reestablishing access to the
active site. In principle, this approach offered potential advantages
over a PFC strategy. First, delays arising from complementation
would not occur, a problem that would manifest at lower
concentrations of enzyme (see Equation 1). Second, complemen-
tation often decreases the intrinsic activity of enzymes and thus a
‘‘native’’ enzyme conformation was preferred. Unfortunately,
although a large number of Fm-TEVp constructs (see ‘‘Supple-
mental methods S1’’) were generated, all retained sufficient
constitutive activity (Fig. S2) to render them inappropriate for
the intended purpose. Consequently, we focused on refining the
PFC strategy to create an effective inducible TEVp system.
Unitary split TEVp constructs
Because our initial sTEVp constructs displayed slow proteolysis
rates following rapamycin addition, we employed several strategies
in an attempt to improve the speed. The first approach utilized
unitary constructs in which the sTEVp fragments were joined
together by a flexible peptide linker. We reasoned that if the
association of separate sTEVp fragments was rate limiting
(Equation 1), the proximity afforded by these constructs (i.e., an
increase in effective concentration) would accelerate the process.
Unitary constructs were created with the linker or FRB/FKBP12
proteins located in different positions (Fig. 3A). The constructs fell
into two broad classes: i) large insertions into the split site
(constructs 1 and 3) or, ii) circularly permuted (swapping of the N-
and C-termini) with or without insertions (constructs 2 and 4). It
was hoped that such dramatic disruptions to the primary sequence
would prevent enzymatic activity until addition of rapamycin
facilitated reconstitution of the active species. Similar strategies
have been used successfully for constructing rapamycin-inducible
luciferase activity [25]. However, in cells transfected with 300 ng
of any of the unitary constructs, there was a large decrease in
median FRET efficiency in both the absence and presence of
Figure 3. Unitary sTEVp constructs have a high background
protease activity. A)( i) Unitary sTEVp plasmids. Locations of the linker
and the FKBP12 and FRB proteins in relation to the TEVp fragments are
shown. The amino acids at the N- and C-termini of the TEVp fragments
are labeled corresponding to their location in the full length TEVp. ii)
Schematic diagram of the unitary sTEVp proteins. B) Scatter plot
showing FRET efficiencies of individual cells transfected with unitary
sTEVp constructs. Cells were transfected with 100 ng of C34V and
600 ng of the unitary sTEVp plasmid. For each construct, FRET
efficiencies were measured from untreated cells (open circles) and cells
treated with rapamycin for 3 hours (solid circles). # represents a
significant difference between the median FRET efficiency of control
cells transfected with C34V alone and cells cotransfected with C34V and
the unitary sTEVp plasmid indicated.
doi:10.1371/journal.pone.0007474.g003
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from control cells transfected with C34V alone, n=28–54). These
results indicated that the unitary sTEVp constructs possessed
substantial enzymatic activity in the absence of rapamycin. Given
the severe disruption of the primary sequence by large insertions
with predicted secondary structure, the retention of enzymatic
activity was surprising and suggested a propensity of the TEVp
fragments to spontaneously re-associate. The inability to modulate
TEVp activity with rapamycin rendered this approach unsuitable.
cis-based sTEVp constructs
TEVp is expressed from the TEV genome as part of a large
polyprotein, which TEVp cleaves in a cis configuration to release
separate viral proteins [26]. This tethered arrangement provides a
very high effective substrate concentration that increases enzyme
velocity (equation 2). Two cis-sTEVp constructs were produced by
fusing one fragment of sTEVp to C34V and expressing the second
fragment of sTEVp from a separate plasmid (Fig. 4Ai,B i). The
advantage of this configuration is that reconstituted enzyme is
exposed to a consistent and high effective concentration of substrate
regardless of expression levels. The disadvantage is that the targeted
molecule requires a larger and more complex modification.
Optimum inducible protease activity for each of the cis-sTEVp
construct was determined by titrating the amount of free sTEVp
construct against a fixed amount (300 ng) of the C34V-fused
construct. In cells transfected with C34V-FRB-TEVnt (Fig. 4Ai),
there was a decrease in FRET efficiency as the amount of FKBP12-
TEVct was increased over the range 0.01–25 ng (Fig. 4Aii). At the
highest concentration tested (25 ng), cleavage was nearly complete
as indicated by a negligible FRET efficiency. In all transfections of
C34V-FRB-TEVnt, rapamycin did not cause a significant change
in FRET efficiency indicating minimal inducible TEVp activity. A
second set of cis-sTEVp constructs comprised of C34V-FKBP12-
TEVct and FRB-TEVnt (Fig. 4Bi) were also tested. In the absence
of rapamycin, cells transfected with $25 ng FRB-TEVnt had a
significant decrease in FRET efficiency compared to cells
transfected with 300 ng C34V-FKBP12-TEVct alone (Fig. 4Bii).
These results were indicative of constitutive protease activity at
higher FRB-TEVnt concentrations. Addition of rapamycin to cells
transfected with 12, 25, and 100 ng FRB-TEVnt caused a
significant reduction in FRET efficiency (Fig. 4Bii). Optimum
inducible TEVp activity occurred in cells transfected with 25 ng
FRB-TEVnt. In these cells, there was little background protease
activity: the median FRET efficiency in the absence of rapamycin
was 84% of the median FRET efficiency measured from control
cells transfected with C34V-FKBP12-TEVct alone (n=27,
ncontrol=19). Following exposure to rapamycin for 3 hours, the
median FRET efficiency fell to 0% of that of the control cells
(n=20), which suggested there was a highlevel of inducible protease
activity. The concentration range over which there was optimal cis-
sTEVp activity was narrow: at higher concentrations of FRB-
TEVnt constitutive activity was apparent while at lower concen-
trations there was insufficient inducible activity.
To investigate the rate of protease activity under the desired
experimental conditions (i.e., those mimicking patch-clamp exper-
iments), cells were transfected with 25 ng FRB-TEVnt construct
plus 300 ng C34V-FKBP12-TEVct. FRET efficiencies were
measured from the same cells during a control period and for 30
minutes after the addition of 100 nM rapamycin. These experi-
ments were performed on the microscope stage at room
temperature. FRET efficiencies were normalized to measurements
taken in the control period. After exposure to rapamycin for 20
minutes, the mean FRET efficiency decreased by approximately
20%(Fig. 4C). Incontrolcells(not exposed torapamycin),there was
a small reduction in FRET efficiency (a reduction of approximately
10%; perhaps indicative of a photobleaching of acceptor (Venus) or
a moderate level of background TEVp activity.
Targeting of sTEVp and substrate to the plasma
membrane
The high effective substrate concentration in the previous two
cis-configuration systems revealed an undesirable propensity of
sTEVp to reconstitute in the absence of rapamycin. Although this
property was evident in the trans-proteolysis experiments (Fig. 2D),
the magnitude of rapamycin-mediated proteolysis was adequate
over a wide range of concentrations. Thus, an intermediate
solution was sought to increase effective substrate concentration,
and hence enzyme velocity, while avoiding overwhelming
constitutive activity. To this end, one fragment of TEVp and the
substrate were targeted to the plasma membrane. Both fragments
of sTEVp were cloned into a single vector (pBud-sol-sTEVp or
pBud-mem-sTEVp; Fig. 5Ai), with each open reading frame
driven by a different promoter, to ensure that the sTEVp
fragments were expressed at a consistent ratio. For localization
to the plasma membrane, a targeting motif (N-terminal myristoy-
lation and palmitoylation) from the protein Lyn [27] was fused to
the N-terminus of C34V (mem-C34V) and the N-terminus of
FKBP12-TEVct (pBud-mem-sTEVp; Fig. 5Ai, ii).
Experiments were carried out to assess cleavage of (cytosolic)
C34V by either cytosolic or membrane-targeted sTEVp. As shown
in Fig. 5Bi, the median FRET efficiency of cells transfected with
300 ng of pBud-sol-sTEVp and 100 ng of C34V was 97% of the
FRET efficiency measured from control cells expressing C34V
alone (P.0.05, n=30, ncontrol=36). In the presence of rapamycin,
the median FRET efficiency of cells transfected with 300 ng pBud-
sol-STEVp decreased to 9% of that of control cells (n=33) and
varied substantially from cell to cell. Cells were transfected with a
higher quantity of pBud-sol-sTEVp (1000 ng) in an attempt to
improve the amount of C34V cleavage. In these cells, there was
small but significant decrease in FRET efficiency in the absence of
rapamycin (84% of the control median FRET efficiency, n=40)
compared with cells expressing C34V alone (see above). In the
presence of rapamycin, the FRET efficiency of cells transfected
with 1000 ng of pBud-sol-sTEVp decreased to 3% of the control
median FRET efficiency (n=33) with little cell-to-cell variability.
This result indicated that at higher concentrations of pBud-sol-
sTEVp, there was an increase in inducible protease activity, but
this was accompanied by increased background activity.
The effect of targeting sTEVp to the membrane on cleavage of
cytosolic C34V was investigated (Fig. 5Bi, right). There was no
significant difference in median FRET efficiency between control
cells transfected with 100 ng C34V alone and cells co-transfected
with either quantity of pBud-mem-sTEVp (the median FRET
efficiency was 100% of that of the control, for both 300 ng, and
1000 ng pBud-mem-sTEVp; n=27 and 23 respectively). Following
treatment with rapamycin, the median FRET efficiency decreased
to 30% of that of the control cells (n=23) for cells transfected with
300 ng of pBud-mem-sTEV, and 12% of that of the control cells
(n=24) for cells transfected with 1000 ng of pBud-mem-sTEV.
These results show that for the soluble C34V, the membrane-bound
sTEVp has a lower amount of background activity, but lower
inducible protease efficiency than the cytosolic sTEVp.
Similar pBud-sTEVp experiments were repeated using the
plasma membrane-targeted substrate, mem-C34V (Fig. 5Bii). In
cells transfected with 300 ng pBud-sol-sTEVp and 100 ng of
mem-C34V, the median FRET efficiency in the absence
of rapamycin was 98% of the FRET efficiency measured from
control cells transfected with mem-C34V alone (n=21,
An Inducible TEV Protease
PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7474Figure 4. Fusion of the substrate to one sTEVp fragment increased background protease activity with no substantial increase in
inducible protease activity. A) cis-sTEVp A. (i) Plasmid expressing C34V fused to FRB-sTEVp. FKBP12-sTEVp was expressed from a second plasmid
(ii) Scatter plot showing FRET efficiencies of cells transfected with 300 ng of C34V-FRB-sTEVp plasmid alone and with increasing amounts of FKBP12-
sTEVp. FRET efficiencies were measured in control cells and in cells exposed to rapamycin for 3 hours. # represents a significant difference of median
FRET efficiencies between the control cells transfected with C34V-FRB-sTEVp alone (first column) and cells cotransfected with the mass of FKBP12-
sTEVp indicated, in the absence of rapamycin. * represents a significant difference between median FRET efficiency measured from cells in the
absence of rapamycin and cells treated with 100 nM rapamycin for 3 hours. B) cis-sTEVp B. (i) Plasmid map and schematic diagram showing C34V
fused to FKBP12-sTEVp. FRB-sTEVp-NT was expressed from a second plasmid. (ii) Scatter plot of FRET efficiencies of cells transfected with 300 ng of
C34V-FKBP12-sTEVp-CT plasmid alone and with an increasing amount of FRB-sTEVp-NT. Details of the graph are equivalent to those described in part
(A), above. C) Time course of cis-sTEVp Construct B activity. Cells were transfected with 300 ng of C34V-FKBP12-sTEVp-CT and 25 ng of FRB-sTEVp-NT.
FRET efficiencies were measured from the same cells, every 30 s and were normalized to the first FRET efficiency measurement, before 100 nM
rapamycin was added. The blue line represents measurements taken from control cells to which no rapamycin was added. Mean 6 SE FRET efficiency
data plotted.
doi:10.1371/journal.pone.0007474.g004
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7474Figure 5. Targeting of one sTEVp fragment and C34V to the membrane increased both inducible and background activity of sTEVp.
A)( i) A single plasmid was used to express both sTEVp fragments. pBud-mem-sTEVp contains a Lyn11 membrane-targeting sequence fused to the N-
terminus of FKBP12-sTEVp-CT. Mem-C34V has a Lyn11 sequence fused to the N-terminus of C34V. (ii) Schematic diagram showing localization of the
Lyn11-modified sTEVp fragment and mem-C34V. B) Scatter plots showing FRET efficiencies of cells transfected with (i) soluble C34V and (ii)
membrane-targeted C34V alone, and with 0.3 mg and 1 mg of pBud-sol-sTEVp or pBud-mem-sTEVp DNA. # represents a significant difference in
median FRET efficiencies between control cells transfected with C34V alone and cells cotransfected with the indicated mass of pBud construct.
* represents a significant difference of median FRET efficiency between untreated cells and cells exposed to 100 nM rapamycin for 3 hours, for a
given mass of pBud-sTEVp plasmid. C) Time course of sTEVp activity. Cells transfected with 100 ng of (i) soluble C34V or (ii) membrane-targeted C34V
alone, and cotransfected with 1000 ng of pBud-sol-sTEVp or pBud-mem-sTEVp. FRET efficiencies were measured every 60 seconds. Where indicated,
rapamycin was added 3 minutes after the start of the experiment. FRET efficiencies were normalized to the mean FRET efficiencies measured before
the addition of rapamycin. Mean 6 SE FRET efficiency data plotted.
doi:10.1371/journal.pone.0007474.g005
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median FRET efficiency was 89% of that of control cells (n=22).
In the presence of rapamycin, there was very large decrease in
FRET efficiency in both cells transfected with 300 ng pBud-sol-
sTEVp (to 7% of control median FRET efficiency; n=23) and
1000 ng of pBud-sol-sTEVp (to 3% of control median FRET
efficiency; n=18), although a number of cells displayed variable
FRET efficiencies. These results suggest that the amount of
inducible cleavage by sol-sTEVp of mem-C34V was high (with the
exception of a few cells).
In cells transfected with pBud-mem-sTEVp, efficient cleavage of
mem-C34V was accompanied by significant background activity. In
the absence of rapamycin, the median FRET efficiency of cells
transfected with 300 ng pBud-mem-sTEVp was 56% of that of
control cells (n=24); in cells transfected with 1000 ng of pBud-mem-
sTEVp the median FRET efficiency was 46% of that of control cells
(n=18). In the presence of rapamycin for 3 hours, the median FRET
efficiency was #4% of that of control cells (n=20 and 23, for 300 ng
and 1000 ng of pBud-mem-sTEVp, respectively).
To investigate the rate of the sTEVp and mem-sTEVp activity,
cells were transfected with 1000 ng of one of the pBud-sTEVp
constructs and 100 ng of C34V or mem-C34V. FRET efficiencies
weremeasuredfromthe samecellsduringa2-minutecontrolperiod
and for 20 minutes after the addition of 100 nM rapamycin on the
microscope stage at room temperature. FRET efficiencies were
normalized to measurements taken in the control period. In cells
transfected with pBud-sol-sTEVp, the mean FRET efficiency
decreased by approximately 30% over 20 minutes after rapamycin
addition (Fig. 5Ci). The change in FRET efficiency varied widely
between cells (see Fig. S3 for the traces of time courses from
individual cells). In the cells transfected with pBud-sol-sTEVp but
with no rapamycin added, there was a small reduction in FRET
efficiency (8% reduction from normalized control FRET measure-
ments, n=10) over 20 minutes. This reduction was mainly due to a
single cell with a large change in FRET efficiency (Fig. S3Aii). In
cells transfected with C34V alone, or cotransfected with pBud-
mem-sTEVp, there was no obvious change in FRET efficiency over
the duration of the experiment. Changes in FRET efficiencies after
rapamycin addition varied widely in cells transfected with mem-
C34V (Fig. 5Cii; Fig. S3). Cells transfected with pBud-mem-sTEVp
or pBud-sol-sTEVp showed substantial but variable decreases in
FRET efficiencies over 20 minutes (a 25% and 40% reduction from
normalized control FRET efficiency measurements, for pBud-
mem-sTEVp and pBud-sol-sTEVp, respectively). The results were
complicated by high levels of background activity (indicated by low
FRET efficiencies in control measurements) in some cells
transfected with pBud-mem-sTEVp. Reliable measurement of very
low FRET efficiencies is difficult, and these inaccuracies are
amplified by normalization. For this reason, cells with control
FRET efficiencies of less than 0.05 (2/8 cells for control recordings,
5/12 cells for recordings in the presence of rapamycin) were not
included in the results displayed in Fig. 5Cii.
An electrophysiological assay for sTEVp activity
An inducibleTEVp system suitable foruse inelectrophysiological
experiments would be desirable. For this reason, an assay in which
inducibleTEVp activitycould beevaluatedintheconditionsandon
the time-scale of an acute electrophysiological experiment was
developed. For the assay, a TEVp substrate consisting of EGFP
fused to the N-terminus of a KV3.4 subunit via a TRS (EGFP-
KV3.4; Fig. 6A) was transfected into HEK-293 cells and currents
through the modified K
+ channel were monitored using whole-cell
patch-clamp recording techniques. TEVp activity was determined
by measuring changes in inactivation of the whole-cell current that
occurred following TEVp-mediated cleavage of EGFP from the
KV3.4 subunit. For these experiments, heterologous expression of
KV3.4constructs was achieved by electroporationof HEK-293with
RNA transcribed in vitro. This method provided high transfection
efficiency and a more uniform level of KV3.4 expression than the
PEI method used in the FRET experiments.
In cells transfected with 500 ng of wild-type KV3.4 RNA,
voltage-dependent,stronglyinactivatingcurrentswereelicitedwhen
the cells were held at 280 mV and stepped to command voltages
(280 mV to +60 mV, in 10 mV increments) for 100 ms (Fig. 6Bi,).
In cells transfected with 500 ng EGFP-KV3.4 RNA, sustained, non-
inactivating, voltage-dependent currents were elicited by the same
voltage protocols as above (Fig. 6Bii). When 2 mg of RFP-TEVp
DNA was co-transfected with 1 mg EGFP-KV3.4 RNA (Fig. 6Biii),
there was substantial (but incomplete) recovery of rapid, voltage-
dependent inactivation. These results are consistent that idea that
the rapid ‘N-type’ current inactivation of the wild-type KV3.4
channel (due to entry of the N-terminal domain into the open
channel pore; 28) was prevented by the bulky EGFP domain fused
to the N-terminus of KV3.4 in EGFP-KV3.4. Cleavage of EGFP
from the modified KV3.4 subunit partially restored N-type
inactivation. TEVp activity could therefore be assessed by
measuring changes in current inactivation in cells expressing
EGFP-KV3.4 and the TEVp construct of interest.
Inactivation (and hence TEVp activity) was quantified from
currentselicitedincellsheldat280 mVandsteppedto+50 mVfor
100 ms (Fig. 6Biv). This voltage protocol generated currents with
robust inactivation that was insensitive to small changes in voltage.
A non-inactivating current of ,0.3 nA, likely to be caused by
endogenous voltage-gated K
+ or Cl
2 channels [29], was elicited by
the 280 to +50 mV step in untransfected HEK-293 cells (data not
shown). For this reason, only currents with peak amplitudes
.1.5 nA were used for inactivation calculations. The ‘degree of
inactivation’wascalculatedusingthe equation 1-(I95ms/Imax), where
I95ms is the amplitude of the current 95 ms after the start of the
voltage step, and Imax is the peak current during the first 50 ms of
the voltage step. Quantification of current inactivation from control
experiments (described above; Fig 6D, left side) shows the working
range of inactivation in this assay: from a median of 0.03 (n=13) in
cells transfected with EGFP-KV3.4 alone (no inactivation/TEVp
activity) to a median of 0.65 (n=14) in cells transfected with EGFP-
KV3.4 and RFP-TEVp (maximum inactivation/TEVp activity).
Inducible TEVp activity was assessed in cells transfected with
either 1 mgo r3mg of pBud-sol-sTEVp DNA, and 1 mg EGFP-
KV3.4. In cells transfected with 1 mg of pBud-sol-sTEVp, the
median inactivation (0.08; n=13) was not significantly different
from cells transfected with EGFP-KV3.4 alone (0.03; n=13;
Fig. 6D). Addition of 100 nM rapamycin for 3 hours did not cause
a significant increase in median inactivation (0.20; n=9). These
results indicate that transfection of 1 mg pBud-sol-sTEVp did not
provide high levels of inducible TEVp activity. In control cells
transfected with an increased mass of pBud-sol-sTEVp DNA
(3 mg), the median inactivation was 0.12 (n=27) with many cells
showing clear inactivation in the absence of rapamycin (Fig. 6Ci
and D), suggesting background protease activity was present.
Following addition of rapamycin for 3 hours, inactivation
increased (median inactivation=0.54; n=14), but the level of
inactivation varied substantially between cells (Fig. 6Cii and D).
Because of the variable level of inducible protease activity
provided by pBud-sol-sTEVp, experiments were carried out using
pBud-mem-TEVp. The increase in apparent TEVp concentration
conferredbymembranetargetingwaspredictedtoincreasethelevel
of substrate cleavage. In cells transfected with 1 mg pBud-mem-
sTEVp, the median inactivation was 0.04 (n=14), which was not
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PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7474Figure 6. An electrophysiological assay of TEVp activity based on changes in inactivation of a modified KV3.4 channel. A) TEVp
activity sensor (EGFP-KV3.4) consisted of an EGFP moiety fused to the N-terminus of a human KV 3.4 subunit via a TRS. (i) EGFP-KV3.4 RNA was
transcribed from a plasmid containing a T7 promoter. (ii) Amino acid sequence of the TRS region of EGFP-KV3.4. The C-terminus of EGFP is shown in
green, the TRS in red, and the N-terminus of KV3.4 shown in blue. The cleavage site is marked with a dashed line. B) Schematic diagrams of KV3.4
constructs and current traces showing the basis of the KV3.4-based assay. Currents were recorded from HEK-293 cells held at 280 mV and stepped to
command voltages (280 mV to +60 mV, in 10 mV increments) for 100 ms. (i) Cells transfected with 500 ng wild-type KV3.4 RNA displayed strongly
inactivating currents. (ii) Inactivation was blocked in cells transfected with 500 ng EGFP-KV3.4. (iii) Cleavage of EGFP from KV3.4 resulted in a partial
recovery of inactivation in cells cotransfected with 1000 ng EGFP-KV3.4 RNA and 2 mg RFP-TEVp DNA. (iv) Current traces from different cells held at
280 mV and stepped to +50 mV for 100 ms. Currents were normalized to the same peak amplitude. Representative traces from cells transfected with
(a) EGFP-KV3.4 RNA (b) EGFP-KV3.4 RNA + rap for 3 hours (c) EGFP-KV3.4 RNA + RFP-TEVp DNA (d) wild-type KV3.4 RNA. C) Typical current traces
showing different levels of inactivation (normalized to the same peak amplitude) from different cells transfected with 1000 ng EGFP-KV3.4+ (i)3mg
pBud-sol-sTEVp DNA (ii)3mg pBud-sol-sTEVp DNA+100 nM rap for 3 hours (iii)3mg pBud-mem-sTEVp (iv) pBud-mem-sTEVp+100 nM rap for 3 hours.
D) Scatter plot showing the amount of current inactivation from cells transfected with the constructs described above. Inactivation was calculated
using the amplitude of the current 95 ms after the start of the voltage step (I95 ms) and the peak current in the first 50 ms of the voltage step (Imax);
see Methods for details. # represents a significant difference in median FRET efficiency, between the cells transfected with EGFP-KV3.4 alone (second
column) and the cells transfected with the indicated pBud-sTEVp, in the absence of rapamycin. * represents a significant difference between the
median FRET efficiency from cells in the absence of rapamycin and cells treated with 100 nM rapamycin for 3 hours, for a given amount of pBud-
sTEVp. E) Plot showing the degree of current inactivation from cells transfected with 3 mg pBud-sTEVp after addition of 100 nM rapamycin.
Recordings were made every 10 s (30 s intervals plotted for clarity) and inactivation was normalized to control currents recorded in the first 2
minutes, before rapamycin addition. Mean 6 SE data plotted. F) Representative traces from cells transfected with pBud-sTEVp before (black trace)
and after addition of rapamycin for 15 minutes (red trace). Examples of cells displaying currents with no inactivation (i, iii) and clear inactivation (ii, iv)
in the control recordings are shown.
doi:10.1371/journal.pone.0007474.g006
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KV3.4 RNA alone (Fig. 6D). In the presence of rapamycin, the
median inactivation of currents from cells transfected with 1 mg
pBud-mem-sTEVp significantly increased to 0.31 (n=11). These
results indicate that in cells transfected with a low quantity of pBud-
mem-sTEVp,thereislittle background activity,buttherewasonlya
modest amount of inducible sTEVp activity. In order to improve
the amount of cleavage, cells were transfected with 3 mg of pBud-
mem-sTEVp. In these cells, inactivation varied highly from cell to
cell, and the median inactivation significantly increased compared
to cells expressing EGFP-KV3.4 alone (median inactivation=0.17;
n=36; Fig. 6Ciii, D). In the presence of rapamycin, there was a
large increase in median inactivation with low variability between
cells (median inactivation=0.53; n=14; Fig. 6Civ, D). These results
indicate that expression of higher quantities of membrane-bound
sTEVp increase inducible TEVp activity but are also associated
with an increase in background activity.
To ascertain whether adequate sTEVp cleavage occurs on a
timescale suitable for acute electrophysiological experiments, the
time course of sTEVp activity was determined in HEK-293 cells
co-transfected with 1 mg of EGFP-KV3.4 RNA and 3 mg of either
pBud-sol-sTEVp or pBud-mem-sTEVp. Recordings were made
from cells in a 2-minute control period and for 18 minutes
following the addition of 100 nM rapamycin. Inactivation was
normalized to the mean inactivation in the control period. In cells
transfected with either pBud-sol-sTEVp or pBud-mem-sTEVp,
the average inactivation changed by ,1% (n=6 and 8) over the
duration of rapamycin exposure (Fig. 6E). Recordings were made
from cells with and without basal inactivation visible in the control
period (Fig. 6F), but addition of rapamycin did not augment
inactivation in either case.
Discussion
In this investigation, we have shown that protein function can be
altered using a rapamycin-inducible TEVp and a TRS inserted into
a protein of interest. The system worked well on a time scale of
3 hours, but the low activity of the sTEVp resulted in insufficient
cleavage of the target protein on a shorter time scale (, 20 min).
This study has identified a number of necessary considerations and
problems encountered when using an inducible TEVp system.
Context and sequence of the TRS
In addition to choosing a location of the TRS so that its
cleavage will have the desired effect on the function of the protein
of interest, this study suggests that cleavage efficiency is very
dependent on the context and sequence of the TRS. Cleavage
efficiency of the canonical TRS was greatly increased when a
FLAG epitope sequence was inserted downstream of the TRS
(Fig. 2). The reason for this improvement is unknown, but the
charged nature of the FLAG sequence may improve access to the
TRS. A previous study has suggested that many different residues,
including methionine, can occupy the P19 position of the TRS
without a significant effect on cleavage efficiency [22]. However,
in our study, insertion of methionine into the P19 position
(C32[M]V) strongly inhibited cleavage. These results suggest that
it is difficult to predict efficient cleavage of the TRS and
optimization of the TRS for each target protein is advantageous.
Evaluation of the efficiency of TRS cleavage in EGFP-KV3.4 is
complicated by unknown effects of N-terminal modification on
channel inactivation. Cells transfected with both EGFP-KV3.4 and
full-length TEVp displayed approximately 70% of the current
inactivation from cells transfected with wild-type KV3.4 alone.
Given that inactivation of wild-type KV3.4 requires only one (of a
possible four) functional N-terminus [30], it is possible that this
incomplete inactivation represent low TRS cleavage. Alternative-
ly, cleavage may be efficient but the presence of any remaining
fused EGFP domains prevents complete inactivation.
Low catalytic efficiency of sTEVp
The limited cleavage of C34V or EGFP-KV3.4 over 20 minutes
suggests that sTEVp has a low catalytic efficiency. Given that Wehr
et al. [14] found that the 118/119 sTEVp had 43% of the activity of
the wild-type TEVp, it is likely that fragment complementation
results in reduced enzyme efficiency. A number of other
complemented enzymes have reduced activity [31–33] (although
exceptions exist; e.g., [34,35]. It is important to consider that wild-
typeTEVp may have an intrinsically lowcatalytic efficiency.The cis
arrangement of TEVp and substrate in the viral polyprotein
provides high apparent concentrations of enzyme. In this
configuration, a very efficient enzyme may not be necessary for
the requisite level of substrate cleavage. Sufficient enzyme activity is
dependent on the nature of the experiment and is difficult to predict
from the published values of Kcat and KM for TEVp [6,11]. These
parameters are dependent on the substrate and experimental
conditions, which were very different to those in our study.
Background activity of sTEVp
In our experiments, attempts to overcome the low catalytic
efficiency of the sTEVp were based on increasing the actual or
apparent concentration of complemented sTEVp. While this
method increased substrate cleavage, its usefulness was hindered
by an increase in TEVp activity in the absence of rapamycin.
Successful protein complementation requires that nonfunctional
fragments of TEVp have a low affinity, and therefore the
probability of fragments associating and reconstituting a functional
enzyme at low concentrations is minimal. Results here are
consistent with significant affinity between TEVp fragments,
which results in a fraction of TEVp fragments that exist as
functional, complemented enzymes. Cleavage of substrate by this
fraction of enzyme is evident when the total concentration of
sTEVp fragments (Fig. 2) or the apparent enzyme concentration is
increased (cis constructs and membrane-targeted constructs; Fig. 4
and 5). In these examples, for a given amount of TEVp fragments,
the proportion of the TEVp fragments that exist as functional
proteases is not predicted to change. In the unitary constructs
(Fig. 3), where the fraction of spontaneously complemented TEVp
fragments is predicted to be higher, clear background activity is
also visible. This type of ‘spontaneous’ refolding/re-association
and reconstitution of catalysis of split enzyme fragments at
relatively low concentrations is well established [36] and
background activity of other split enzyme complement systems
have been attributed to the high affinity between fragments
[25,37]. Assuming that our 118/119 sTEVp has significant
affinity, any attempt to overcome the low catalytic efficiency by
increasing apparent/actual sTEVp concentration is likely to result
in a concomitant increase in background activity. An alternative
method to improve substrate cleavage by increasing the intrinsic
sTEVp catalytic efficiency is likely to be challenging. The easiest
approach to increase substrate cleavage may be to reduce the
background activity, which would permit increased levels of
sTEVp fragment expression (and thereby increase the amount of
inducible TEVp). A previous study showed that a single point
mutation to one of the fragments of a complemented protein,
which was predicted to lower the affinity between the fragments,
reduced background activity [37]. Perhaps a similar mutation
would be successful with sTEVp.
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complementation. Although the amount of C34V cleavage by 90/
91 sTEVp was lower than 118/119 sTEVp (Fig. 2), the low
background activity may allow methods that increase apparent/
actual sTEVp concentration to compensate for the low catalytic
efficiency. Alternative, untested, TEVp split sites also have the
potential to lower affinity between fragments, although the obvious
choices based on criteria proposed by Michnick et al. [38] have
been tested in this investigation.
Inducible TEVp using Fm proteins
The second method to develop an inducible TEVp using Fm
proteins was, as yet, unsuccessful. This technique has potential
advantages over protein fragment complementation in that it is
reversible and rapid [24]. This approach is less disruptive to the
TEVp active site than protein complementation, which may
improve the catalytic efficiency of an inducible TEVp. Because of
these advantages, occlusion of the active site by Fm moieties merits
further investigation. Circular permutation of TEVp may uncover
alternative N- and C- termini which, when bound to FM moieties,
occlude the active site more effectively.
Application of the sTEVp system to other target proteins
This investigation aimed to develop an inducible sTEVp with
high catalytic efficiency and low background activity for single cell
experiments, which may be inherently challenging. The variable
nature of transfection leads to large differences in sTEVp
expression levels from cell to cell and is likely to account for some
of the high background activity and/or low substrate cleavage
observed in these experiments. Despite this variability, a number
of individual cells expressing pBud-sol-sTEVp had little back-
ground activity and good levels of C34V cleavage after 3 hours
(Fig. 5B) and more than 50% Lyn-C34V cleavage in 20 minutes
(Fig. 5Cii and S3 Biii). If the variability of expression levels could
be better controlled, careful titration of the sTEVp pieces may
provide the low background and efficient inducible protease
activity necessary. It is difficult to predict how the inducible TEVp
system would perform for other target proteins because the
necessary level of inducible protease activity and acceptable level
of background activity will be dependent on the aim and
conditions of experiment. The level of inducible TEVp activity
demonstrated in this study may be sufficient for other applications,
especially experiments in which the cell-to cell variability poses less
of a problem; for example, in cell lysates, where measurements are
averaged from a large number of cells.
There are many applications for an inducible TEVp system for
functional characterization of proteins. In particular, the ability to
ablate the function of a chosen protein on a rapid scale is likely to
be especially useful for the elucidation of a particular function of a
protein that has multiple interrelated but temporally distinct roles.
For example, investigation of the role of voltage-gated Ca
2+-
channel b-subunits in channel gating is impeded by the additional
role of the b-subunit in trafficking the pore-forming a-subunit to
the plasma membrane. The ability to abolish b-subunit function
after it has completed its trafficking role is likely to provide
considerable insights into its gating function.
If the level of inducible and background protease activity can be
optimized, the sTEVp system provides a tool for studying protein
function in vivo. Ideally, it would be possible to ablate endogenous
protein function in vivo using an inducible, rationally designed
protease selective for a chosen sequence. Unfortunately, the
development of rationally designed proteases has been slow and
insights into the mechanism of substrate specificity of TEVp have
demonstrated the high complexity of this task [39]. In the absence
of such a protease, TEVp has been used to investigate protein
function in vivo in genetically malleable model organisms. In these
systems, the endogenous protein was replaced by the protein
containing a TRS: in E. coli [40] and S. pombe [41], a ‘knock-in’
technique was used to replace a chosen gene with the gene
containing a TRS; in Drosophila, a mutant deficient in the gene of
interest was rescued by transgenic expression of the gene
containing a TRS [42]. In these examples, TEVp was expressed
from a transgene under control of an inducible promoter. The
application of similar knock-in/transgenic strategies for mamma-
lian models is more challenging, but using these methods
combined with the ability to express TEVp in particular tissues
using cell-type specific promoters [42] and the temporal
advantages of using sTEVp to control TEVp activity has the




HEK-293 and HeLa cells (ATCC, Manassas, VA) were
cultured at 37uC, 5% CO2 in Minimal Essential Medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (Hyclone, Logan, UT) and 100 units/ml penicillin, 100 mg/
ml streptomycin (Invitrogen).
Heterologous expression
For the FRET experiments, a suspension of approximately 5610
5
HeLa cells were transfected with plasmid DNA using fully de-
acylated polyethylenimine [PEI; 43] at a nitrogen:phosphate of 6.
Cells were added to a 12-well plate and incubated for overnight at
37uC, 5% CO2. 2 h before imaging, cells were replated onto 35 mm,
collagen-coated, glass-bottomed petri dishes (Mattek, Ashland, MA).
For electrophysiological recordings, approximately 2610
6
HEK-293 cells were transfected using a pipette-based electropo-
ration device (MicroPorator MP-100; Harvard Apparatus, Hollis-
ton, MA), according to manufacturer’s instructions. Briefly, cells
were resuspended in 50 ml of ‘R’ solution with 0.25–1 mgK V3.4
RNA, 1–3 mg sTEVp DNA and 0.1 mg pRFP-C1 DNA (as a
tracer), as applicable. The electroporation parameters were 3
pulses of 1300 V, each pulse for a duration of 10 ms. Transfected
cells were incubated overnight at 37uC, 5% CO2. 2 h prior to
recording, cells were replated onto 35 mm plastic petri dishes.
FRET studies
A widefield, inverted IX71 microscope (Olympus, Center
Valley, PA), equipped with a PlanApo 606 1.4 NA objective
(Olympus), an X-cite Series 120PC mercury-halogen arc lamp
(EXFO, Mississauga, ON, Canada) and a 12 Bit Retiga EXi CCD
camera (QImaging, Surrey, BC, Canada) was used. Optical filters
consisted of a dual CFP/YFP filter cube, CFP filter set (excitation
430/24 nm, emission 470/24 nm) and YFP filters (excitation 500/
20 nm, emission 535/30 nm; all from Chroma, Rockingham,
VT). The filters were mounted in filter wheels controlled by a
Lambda 10–2 filter changer (Sutter, Novato, CA). Image
acquisition and processing, camera control, and operation of the
filter wheels were performed using custom-written IGOR Pro 6.0
(Wavemetrics, Lake Oswego, OR) procedures (S. Ikeda). Calcu-
lation of FRET efficiencies and FRET efficiency standards were
described previously [20].
Electrophysiology
Currents were recorded using conventional whole-cell patch-
clamp techniques. Recordings were obtained using an Axopatch
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pipettes were fabricated from Corning 8250 borosilicate glass
capillaries (World Precision Instruments, Sarasota, FL) using a P-
97 Flaming-Brown micropipette puller (Sutter Instruments,
Novato, CA). Pipettes were coated with Sylgard (Dow-Corning,
Midland, MI) and fire-polished to a final resistance of approxi-
mately 2 MV when filled with internal solution. Voltage protocol
generation and data acquisition were carried out using custom-
designed software (S5) running on a Mac G4 computer (Apple,
Cupertino, CA). Currents were filtered at 10 kHz using a four-
pole low-pass Bessel filter, and digitized at 10 kHz. Uncompen-
sated series resistance was ,5 MV and was electrically
compensated to approximately 90%. The external recording
solution contained (in mM): 140 NaCl, 5.4 KCl, 10 HEPES, 0.8
MgCl2, 2 CaCl2, 15 Glucose. The pH was adjusted to 7.4 using
NaOH. The pipette solution contained (in mM) 0.1 CaCl2,1 1
EGTA, 10 HEPES, 120 potassium isethionate, 20 KCl, 4
MgATP, 0.1 Na2GTP. The pH was adjusted to 7.4 using KOH.
The osmolality of the external and internal solutions were adjusted
with sucrose to 315 and 290 mOsm, respectively. All recordings
were carried out at room temperature (20–22uC).
A noninactivating current of ,0.3 nA, likely to be caused by
endogenous voltage-gated K
+ or Cl
2 channels [29], was elicited by
the 280 to +50 mV step in untransfected HEK-293 cells (data not
shown). For this reason, only currents with peak amplitudes
.1.5 nA were used for calculations of inactivation.
Molecular Biology
Standard PCR- and restriction-based cloning techniques were
used in the construction of cDNA plasmids for this study. See
‘‘Supplemental methods S1’’ file for full details of the cDNA
constructs. Briefly, the FRET based TEVp sensors were
modifications of the previously described C32V construct [44].
Codon optimized TEVp (GenBank accession # DQ516974) was
synthesized (Genescript, Piscataway, NJ) and cloned into a
modified pCI (Promega, Madison, MI) expression vector. TEVp
fragments were fused to the rapamycin binding partners FKBP12
(accession number U69485) and the FRB domain of FRAP1/
mTOR (accession number NM_019906; residues 2018–2114)
which have been described elsewhere [45]. Human KV3.4
(KCNC4; transcript variant 1; NM_004978) was amplified by
the PCR from human whole-brain cDNA (BD Biosciences,
Franklin Lakes, NJ). For RNA expression, KV3.4 constructs were
sub-cloned into a custom vector containing a T7 promoter. RNA
was transcribed from linearized plasmid DNA using mMESSAGE
mMACHINE T7 kit (Ambion, Austin, TX) according to the
manufacturer’s instructions. The quality of the RNA was assessed
on a gel and the concentration was determined by measuring the
absorbance at 260 nm.
Data analysis
Data were analyzed using IgorPro 6.0 and Prism 5.0 (GraphPad
Software, San Diego, CA). Statistical comparisons were made
using Kruskal-Wallis one-way ANOVA test with Dunn’s post test,
where appropriate. P values,0.05 were considered significant.
Supporting Information
Supplemental Methods S1
Found at: doi:10.1371/journal.pone.0007474.s001 (0.45 MB
DOC)
Figure S1 Constructs were made containing TEVp fragments
without the rapamycin-binding proteins. Scatter plot showing
FRET efficiency measurements from cells transfected with 100 ng
C34V and increasing amounts of 118/119 sTEVp constructs. #
represents a significant difference of the median FRET efficiency
between the control cells transfected with C34V alone (first column)
and cells cotransfected with the mass of 118/119 sTEVp construct
indicated. B) Time course of 118/119 sTEVp activity at 33uC. A
plot showing the median FRET efficiencies of different cells
transfected with 300 ng of 118/119 sTEVp (with FRB/FKBP12
domains) constructs at varioustime points after rapamycin addition.
Thetimeconstant(t)wascalculated froma single-exponential curve
fitted to the data (n=23–29 cells at each time point).
Found at: doi:10.1371/journal.pone.0007474.s002 (0.85 MB TIF)
Figure S2 Occlusion of the TEVp active site using the Fm
mutant of FKBP12 was unsuccessful. A) Schematic diagram
showing a potential method of controlling TEVp activity by
rapamycin-dependent occlusion of the active site by Fm moieties.
B) Fm-Cerulean and Fm-Venus plasmid constructs. C) Schematic
diagram showing the rapamycin-dependent interaction of Fm-
Venus and Fm-Cerulean. D) A scatter plot showing FRET
efficiencies of different cells transfected with 100 ng of Fm-Venus
and 100 ng of Fm-Cerulean without rapamycin, after exposure to
100 nM rapamycin for 3 hours, and 3 hours after the washout of
rapamycin. E) Fm-TEVp plasmids. An FM moiety was fused to
both ends of full-length TEVp and TEVp with N- and C-terminal
truncations. The numbers correspond to the amino acid position
on the full-length TEVp. F) Scatter plot showing FRET
efficiencies measured from cells transfected with 100 ng of C34V
alone and cells cotransfected with 300 ng of Fm-TEVp plasmids.
# represents a significant difference of median FRET efficiency, in
the absence of rapamycin, between control cells transfected with
C34V alone (first column) and cells cotransfected with the
indicated Fm-TEVp construct. * represents a significant difference
between control cells (in the absence of rapamycin) transfected
with the indicated Fm-TEVp construct and cells treated with
100 nM rapamycin for 3 hours. G) Constructs containing different
linkers between the Fm and TEVp, and multiple copies of the Fm
protein were tested. H) A scatter plot showing FRET efficiencies of
different cells cotransfected with 100 ng C34V and 300 ng of Fm-
TEVp plasmids. I) A schematic diagram showing attempts to block
the active site with free Fm proteins and Fm-TEVp constructs. J)
Scatter plot showing FRET efficiencies measured from cells
cotransfected with 100 ng C34V and 300 ng of Fm-TEVp
plasmids with (open circles) and without (closed circles) 300 ng
of free Fm plasmid.
Found at: doi:10.1371/journal.pone.0007474.s003 (1.60 MB
DOC)
Figure S3 Time course of pBud-sTEVp activity in individual cells.
A) Cells were transfected with 100 ng of soluble C34V alone (i), or
cotransfected with either 1000 ng of pBud-sol-sTEVp (ii, iii) or
1000 ng pBud-mem-sTEVp (iv,v). FRET efficiencies weremeasured
every 60 seconds for 20 minutes. Control recordings were made in
the absence of rapamycin (ii, iv). For experiments in the presence of
rapamycin (iii, v), 3 minutes of control measurements were made
prior to the addition of 100 nM rapamycin. B) Cells transfected with
100 ng of mem-C34V. sTEVp constructs and rapamycin treatment
are the same as (A).
Found at: doi:10.1371/journal.pone.0007474.s004 (1.40 MB
DOC)
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